Kuros Biosciences announced that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrolment in the PARTNER clinical trial, the first patient treated with MagnetOs Flex Matrix and reaching a total of 10,000 patients treated with MagnetOs worldwide. PARTNER is the first of five Level 1 randomized controlled trials for MagnetOs to be fully enrolled and conducted under the umbrella research program known as Project Fusion, which compares MagnetOs to the gold standard of autograft bone. A total of 30 patients with leg pain and/or back pain, requiring up to three-level instrumented posterolateral lumbar fusion (L2 - S1), were included in the study and an interim analysis will be performed once the first 15 patients have completed their Month 6 visit with available measurements for the endpoints.

The first patient was treated with MagnetOs Flex Matrix, which opens up an opportunity for the 62% of all U.S. spine surgeons who routinely mix their bone graft of choice with bone marrow aspirate, by Dr. Terrence Crowder at the Arizona Spine and Joint Hospital. MagnetOs Flex Matrix was mixed with autograft and used in a posterolateral fusion over the facets in a patient with degenerative disc disease. MagnetOs Flex Matrix is a new open matrix bone graft with a unique fibrillar and flexible structure that optimizes the effect of Kuros' established NeedleGrip surface technology and is extremely convenient to use with strength and flexibility.